共 298 条
[1]
Heeringa J(2006)Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 949-953
[2]
van der Kuip DA(2009)Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study Eur Heart J 30 1128-1135
[3]
Hofman A(2008)Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial) Am J Cardiol 101 634-638
[4]
Kors JA(2015)Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 373 2117-2128
[5]
van Herpen G(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[6]
Stricker BH(2017)Optimizing the analysis strategy for the CANVAS program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials Diabetes Obes Metab 19 926-935
[7]
Du X(2014)Atrial remodeling and atrial fibrillation: recent advances and translational perspectives J Am Coll Cardiol 63 2335-2345
[8]
Ninomiya T(2014)Modeling type 2 diabetes in rats using high fat diet and streptozotocin J Diabetes Invest 5 349-358
[9]
de Galan B(2010)Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats Neurobiol Learn Mem 94 293-302
[10]
Abadir E(2014)Combination of the sodium–glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet Diabetes Metab Syndr Obes 7 265-275